Condition
Sickle Beta Thalassemia
Total Trials
4
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Early P 1 (1)
Trial Status
Completed2
Withdrawn1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05675436Active Not Recruiting
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
NCT06831799Completed
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
NCT04776850Early Phase 1Withdrawn
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
NCT02258997Completed
Hepcidin Levels in Sickle Cell Disease (SCD)
Showing all 4 trials